Abstract The ErbB2/3 heterodimer plays a critical role in breast cancer progression and in the development of endocrine resistance. EBP1, an ErbB3 binding protein, inhibits HRG-stimulated breast cancer growth, decreases ErbB2 protein levels and contributes to tamoxifen sensitivity. We report here that ectopic expression of EBP1 in Estrogen Receptor (ER) positive breast cancers that express ErbB2 at both high and low levels decreased ErbB2 protein levels. ErbB2 protein expression was also increased in mammary glands of Ebp1 knock out mice. To define the mechanism of ErbB2 down regulation, we examined the effects of EBP1 on ErbB2 mRNA levels, transcription of the ErbB2 gene and ErbB2 protein stability. We found that ectopic expression of EBP1 decreased steady state levels of endogenous ErbB2 mRNA in all cell lines tested. EBP1 overexpression decreased the activity of an ErbB2 promoter reporter in cells which overxpress ErbB2. However, reporter activity was unchanged or increased in cells which express low endogenous levels of ErbB2. We also found that ectopic expression of EBP1 accelerated ErbB2 protein degradation and enhanced ErbB2 ubiquitination in cells which express both low and high levels of ErbB2. Treatment with proteasome inhibitors prevented this decrease in ErbB2 protein levels. Ablation of EBP1 expression led to tamoxifen resistance that was abrogated by inhibition of ErbB2 activity. These results suggest that EBP1 inhibits expression of ErbB2 protein levels by multiple mechanisms and that EBP1's effects on tamoxifen sensitivity are mediated in part by its ability to modulate ErbB2 levels.
Introduction
A wealth of clinical data has demonstrated the aberrant expression of ErbB family members in breast cancer [1] [2] . The ErbB2 gene is amplified in 20-30% of breast carcinomas contributing to more aggressive disease [3] . The overexpression of ErbB2 has been successfully exploited therapeutically by use of the monoclonal antibody Trastuzumab and by tyrosine kinase inhibitors. ErbB3 is also overexpressed in many breast tumors [4] and coexpression of ErbB2 and ErbB3 is significantly associated with decreased survival [5] . Oncogenic signaling through ErbB3 can abrogate the effectiveness of ErbB directed therapies [6] . The ErbB2/ ErbB3 receptor pair forms the most potent mitogenic receptor complex in vitro [7] and is key to the proliferation of human breast cancer cells that express these receptors [8] .
Endocrine resistance is often associated with the enhanced expression of members of the ErbB receptor family, especially ErbB2. Multiple clinical studies indicate that ErbB2 expression portends a poorer prognosis with tamoxifen therapy [9] . This is important as approximately half of breast cancers that overexpress ErbB2 also express hormone receptors [10] . It has been demonstrated in both cell culture and animal models for many years that the enhanced expression of ErbB2 leads to the ability of cells to bypass normal endocrine responsiveness [11] [12] .
The biological activity and expression of ErbB2 and ErbB3 are regulated by a host of interacting proteins that may be potential targets for development of new therapies. Our laboratory has been interested in proteins that regulate ErbB3, as the ErbB3 receptor has impaired tyrosine kinase activity [13, 14] , necessitating its interactions with other proteins to exert its biological effects. An ErbB3 binding protein (EBP1) was isolated in our laboratory during a yeast two-hybrid screen for ErbB3 interacting proteins [15] . Overexpression of EBP1 inhibits growth of ErbB2/3 expressing cell lines. Ectopic expression of EBP1 promotes G2/M cell cycle arrest and cellular differentiation [16] . Overexpression of EBP1 inhibits the transcription of reporter genes controlled by Cyclin D1, Cyclin E, and cmyc promoters, and the transcription of endogenous E2F1 and c-myc genes via its binding to an E2F1 consensus element [17] [18] [19] . The ability of EBP1 to repress transcription requires its interaction with histone deacetylase 2 (HDAC2), Rb and Sin3A [18, 19] [20] .
Our previous study has demonstrated that ectopic expression of EBP1 inhibits growth of MCF-7 and AU565 breast cancer cell lines in response to HRG and interferes with HRG-induced growth signals, such as the activation of AKT. In addition, ErbB2 protein levels are decreased in MCF-7 and AU565 cells transfected with EBP1 [21] . In the current study, we were interested in determining the mechanism of ErbB2 downregulation in ER ? breast cancer cells. We found that EBP1 decreased steady state levels of ErbB2 mRNA in all cell lines tested. However, ErbB2 promoter activity was decreased only in cells which overexpress ErbB2. EBP1 decreased ErbB2 protein stability in cells which express both high and low levels of ErbB2 via a proteasome-mediated pathway. We also found that tamoxifen resistance induced by ablation of EBP1 expression was abrogated by inhibition of ErbB2 activity.
Materials and methods
Cell culture MCF-7, T47D, and BT474 cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained at 37°C in a humidified atmosphere of 5% CO 2 in air in RPMI 1640 (Biofluids, Rockville, MD) and 10% FBS (Sigma, St. Louis, MO).
Reagents
Heregulin b1 (HRGb1) was obtained from R & D Systems Inc. (Minneapolis, MN), EGF and 4-hydroxy-tamoxifen (OHT) from Sigma, and Geneticin (G418) from Invitrogen (Carlsbad, CA). The proteasome inhibitor ALLnL was from Sigma and MG132 from Calbiochem (San Diego, CA).
Plasmids
A full-length EBP1 cDNA(GenBank NM006191) was generated by PCR with specific reverse and forward primers containing EcoRI and BamHI restriction sites using a pcDNA-EBP1 vector as a template [17] . This cDNA includes all three possible translation initiation sites of EBP1 and encodes the largest form of the protein. The EGFP-EBP1 plasmid was constructed by cloning fulllength EBP1 into the BamHI/EcoRI sites of the pAGFP1-Hyg-C1 vector (Clontech, Palo Alto CA) and the EcoRI/ BamHI sites of the CMV10 vector (Sigma) respectively. The pcDNA3 ErbB2 expression plasmid was a generous gift of Dr. Yossi Yarden.
Creation of stably transfected cell lines
To establish EBP1 overexpressing stable transfectants, subconfluent cells in 100-mm tissue culture dishes were transfected with 10 lg of EGFP, or EGFP-EBP1 expression plasmids using Fugene-6 (Roche, Indianapolis, IN) according to the manufacturer's protocol. Cells were selected in G418 (500 lg/ml) for 4 weeks and mass cultures obtained.
To generate EBP1-silenced cell lines, cells were seeded into 96 well plates and transduced with lentiviral particles (MOI 25) with shRNA targeted to NT 302-322 of the PA2G4 (EBP1) (Genbank NM_006191.1) gene (Mission shRNA, Sigma) according to the manufacturer's protocol. Cell lines were selected in 2 lg/ml of puromycin and surviving colonies of cells expanded as mass cultures. Four independent transductions of this lentiviral construct were performed and designated Clones 1-4. The control was an EBP1-directed lentivirus (NT 776-793) that was previously demonstrated not to change EBP1 expression [22] .
Western blot analysis
Total cell extracts were prepared by direct lysis of cells with lysis buffer [50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 250 mM NaCl, 1% Triton X-100, 0.5 mM DTT, and 1x Complete TM protease inhibitor]. Protein concentrations were measured using a detergent compatible kit (Bio-Rad, Richmond, CA). Proteins (30 lg per well) were resolved by SDS-PAGE, transferred to PVDF membranes, and immunoblotted as described [15] . The EBP1 antibody was from Upstate (Lake Placid, NY), the anti-actin and GAP-DH antibodies from Sigma, the ubiquitin antibodies were from Cell Signaling (Danvers, MA). Images were quantified using IMAGE-J software (NIH). Where indicated, blots were stripped in Restore Western blot Stripping Buffer TM (Pierce, Rockford, IL) as directed by the manufacturer and reprobed.
Immunohistochemical analysis
Mammary glands (#4) were excised and fixed in 10% buffered neutral formalin. Sections of formalin-fixed, paraffin-embedded tissues were cut to 5 lm. Slides were stained with rabbit ErbB2 and EBP1 antibodies (both from Upstate) diluted 1:100 using the standard avidin-biotin method (Vecta-Stain Kit, Vector Labs, Burlinghame, CA) with Harris hematoxylin as a counterstain [23] .
Cell growth assays
For studies assessing the effect of tamoxifen on cell growth, cells (5 9 10
3 ) were plated in 96 well plates in complete media. After a 24-h attachment period, the medium was replaced with complete medium containing hydroxy-tamoxifen (OHT) at the indicated concentrations. Relative live cell numbers were determined at Day 4 using a Promega Proliferation Reagent (Promega, Madison,WI) as per manufacturer's instructions with absorbance being read at 490 nm using a Dynex plate reader.
RNA isolation and PCR analysis RNA was extracted from whole cell lysates, DNAse treated and converted into cDNA using an AMV reverse-transcription system (Promega) in the presence of random hexamers (Invitrogen).The cDNA was used for conventional PCR or quantitative real-time PCR (RT-qPCR) with specific gene primers as follows: ErB2 forward 5 0 -gggaagaatggggtcgtcaaa 3 0 or agccgcgagcacccaagt and reverse 5 0 -ctcctccctggggtgtcaagt or ttggtgggcaggtaggtgagtt GAPDH (NM_002046): forward 5 0 -ccacccatggcaaattcc-3 0 and Reverse 5 0 -tcgctcctggaagatggtg. An MYIQ real-time PCR detection system and SYBR green PCR mix (BioRad) were used to carry out the real-time PCR. The relative quantitation of targeted genes was determined by the comparative DDCt (threshold) method using GAPDH as an internal control [24] . All data were analyzed from three independent experiments and statistical significance was validated by Student's t-test.
Dual luciferase assay 5 9 10 4 cells/well were transfected with 0.5 lg of GFP or GFP-EBP1, 0.5 lg of ErbB2-luc (a firefly luciferase reporter gene under the control of the -500 to ?1 region of the ErbB2 promoter [25] and 5 ng of the pRL-TK vector (a Renilla luciferase reporter gene under the control of the thymidine kinase promoter) using Fugene 6. Forty-eight hours after transfection, cells were lysed and luciferase activity determined using a dual luciferase reporter assay (Promega). The activities of Renilla luciferase were used to normalize any variations in transfection efficiency.
Statistical analysis
Data were analyzed using a two-tailed Student's t-test and a P \ 0.05 was deemed statistically significant.
Results

Modulation of EBP1 expression affects ErbB2 protein levels
Our previous published results indicated that ectopic expression of EBP1 decreased protein levels of ErbB2 in MCF-7 (ER?) and AU565 (ER-) cells [21] . Overexpression of ErbB2 is a major problem in development of endocrine resistance in ER? cell lines [9] and devising new ways to decrease ErbB2 levels are important for future therapeutic development. We were, therefore, interested in assessing the effects of EBP1 in ER? cells lines that express ErbB2 at both high and low levels. We overexpressed EBP1 in ER? ErbB2 high BT474 cells and ER?, ErbB2 low T47D cells. Ectopic expression of EBP1 decreased ErbB2 levels three fold in BT474 cells and five fold in T47D cells as determined by densitometric analysis (Fig. 1a, b) . However, the levels of ErbB2 in BT474 EBP1 transfectants were still much greater than those observed in control T47D cells. Elimination of EBP1 expression by shRNA in T47D cells enhanced ErbB2 protein levels four fold (Fig. 1c) as we previously described for MCF-7 cells [21] .
To further determine the physiological effect of Ebp1 on endogenous ErbB2 levels, we examined expression of ErbB2 in adult mammary epithelium in a knock out mouse we recently developed [26] . We found that in mammary epithelial cells, ErbB2 expression was increased in mammary tissue of Ebp1 -/-10 week old female mice (Fig. 1d) .
Steady state mRNA levels are decreased after EBP1 transfection
To determine a mechanism for the decreased protein levels of ErbB2, we first examined steady state ErbB2 mRNA levels in EBP1 transfected and control cell lines which express high (BT474, AU565) or low (MCF-7, T47D) levels of ErbB2. The expression of the EBP1-GFP transgene is shown in Fig. 1 a,b for T47D and BT474 cells lines. The expression of the FLAG-tagged EBP1 in the AU565 and MCF-7 EBP1 transfectants has previously been published [21] . We found by RT-qPCR that ectopic expression of EBP1 led to statistically significant decreases in steady state ErbB2 mRNA levels in all cell lines tested (Fig. 2) . ErbB2 mRNA levels were decreased about 50% in BT474, AU565, and MCF-7 cells, and 66% in T47D cells. However, the levels of ErbB2 mRNA found in BT474 and AU565 cells stably overexpressing EBP1 were significantly higher than those found in control T47D and MCF-7 cells. Thus, while EBP1 overexpression lowers ErbB2 mRNA levels in cells expressing high levels of ErbB2, mRNA levels do not reach those observed in cells with normally low endogenous levels.
Ectopic expression of EBP1 affects the activity of the ErbB2 promoter
We next determined if EBP1 could affect ErbB2 transcription using an ErbB2 promoter-luciferase reporter that encodes the 500-bp proximal promoter upstream from the 
A representative field is shown transcription start site. Transient transfection of EBP1 into COS7, BT474, and AU565 cells led to significant decreases in reporter activity (Fig. 3a) . However, the level of reporter activity in BT474 EBP1 transfectants was higher than that observed in T47D controls. In contrast, the activity of the reporter was not significantly changed in T47D and significantly increased in MCF-7 cells (Fig. 3a) . In EBP1 stable BT474 transfectants, a statistically significant 58% decrease in luciferase activity was observed as compared to vector controls (Fig. 3b) . No changes in reporter activity were observed in T47D stable EBP1 transfectants (Fig. 3b) .
Effects of EBP1 on ErbB2 protein stability As ErbB2 protein levels were decreased more than mRNA in both the BT474 and T47D EBP1 stable transfectants, we next examined ErbB2 protein stability. ErbB2 protein levels have been demonstrated to be regulated by proteasome-mediated degradation [27] . We examined ErbB2 levels after inhibition of protein biosynthesis with cycloheximide (20 lg/ml). We found that in BT474 cells, the expression of ErbB2 protein was significantly lower at 8 h after cycloheximide treatment as compared to vector controls (Fig. 4a) . In T47D cells, ErbB2 protein levels were also lower after 8 h of cycloheximide treatment in EBP1-transfected cells (Fig. 4b ) as compared to vector controls.
We next determined if the increased ErbB2 degradation observed after ectopic expression of EBP1 could be rescued by proteasome inhibition. We used the proteasome inhibitors MG132 and ALLnL to stabilize ubiquitinated ErbB2 in BT474 and T47D cells in which EBP1 had been overexpressed. As expected, ErbB2 levels in the absence of the inhibitor were decreased in both the BT474 and T47D EBP1 transfectants as compared to controls (Figs. 5a, b) . ErbB2 levels were increased when EBP1 was ablated in T47D cells (Fig. 5b) . Addition of ALLnL was able to overcome the decrease in ErbB2 protein observed in BT474 EBP1 transfectants. However, MG132 was not able to restore ErbB2 levels (data not shown). This is of interest as ALLnL inhibits the activity of both the proteasome and calpain I [27] . In T47D EBP1 transfectants both MG132 (Fig. 5b) and ALLnL (data not shown) resulted in restoration of ErbB2 levels. In EBP1-silenced cells, ErbB2 levels were slightly decreased in the presence of the proteasome inhibitor (Fig. 5b) . EBP1 itself has been demonstrated to be a target of ubiquitination. Two isoforms of EBP1 have been reported: a p42 pro-apoptotic form and a p48 anti-apoptotic form. The p42 isoform appears to be preferentially degraded in cancer cells [28] . However, endogenous EBP1 levels were not increased by proteasome inhibitors in either cell line at this time point. Only the 48kD form of EBP1 was observed (Fig. 5a, b) . The GFP-EBP1 fusion protein continued to be overexpressed at about the same level (data not shown). Since ErbB2 is degraded through a mechanism that involves its polyubiquitination [29] , we tested if ectopic expression of EBP1 could elevate ubiquitination of ErbB2. Examination of whole cell lysates revealed that treatment with proteasome inhibitors increased ubiquitination as expected (Fig. 5c, d left panels) . ErbB2 was next immunoprecipitated from lysates of cells treated with proteasome inhibitors for 6 h and proteins analyzed by western blotting with anti-ubiquitin and ErbB2 antibodies. Ubiquitination of ErbB2 was enhanced by treatment with proteasome inhibitors as expected [27] in BT474 cells (Fig. 5c, right panel) . In contrast, ubiquitinated ErbB2 was not observed in the presence of MG132 in T47D GFP controls. This suggests that there is a very low steady state level of ubiquitination of ErbB2 in control T47D cells. ErbB2 ubiquitination was increased in EBP1-transfected cells as compared to vector controls for both cell lines (Fig. 5c, d right panels) .
EBP1 affects the response to tamoxifen through an ErbB2-mediated pathway We first tested if ectopic expression of EBP1 could enhance tamoxifen sensitivity. We found that sensitivity to low doses of tamoxifen was significantly enhanced in T47D EBP1 transfectants (Fig. 6a) . To determine if this enhanced sensitivity was due to a decrease in ErbB2 levels, we transiently transfected an expression plasmid for ErbB2. This resulted in a reversal of the effects of EBP1 on tamoxifen sensitivity and induction of tamoxifen resistance (Fig. 6a) as previously demonstrated.
We previously showed that elimination of EBP1-induced tamoxifen resistance in MCF-7 cells and upregulated ErbB2 expression [21] . Similarly, Fig. 1C shows that ErbB2 expression was upregulated after elimination of EBP1 expression in T47D cells. We, therefore, determined if silencing of EBP1 could also induce tamoxifen resistance in T47D cells. EBP1-silenced cells were treated with OHT and cellular sensitivity assessed. EBP1 knock out cells (now ER? and ErbB2 high) were no longer sensitive to OHT (Fig. 6b) . To determine if the tamoxifen resistance that occurred after EBP1 silencing was due primarily to the increase in ErbB2 levels, we treated EBP1 knock out T47D cells with the anti-ErbB2 antibody Herceptin in addition to OHT. We found that Herceptin restored sensitivity to tamoxifen that had been lost due to EBP1 silencing (Fig. 6c, left panel) , suggesting EBP1's primary mechanism of action may be via decreases of ErbB2 levels. In contrast, Herceptin treatment had no effect on the growth or the response to tamoxifen of T47D cells transduced with a control lentivirus (Fig. 6c, right panel) .
Discussion
Increasing data support the clinical importance of specific ErbB heterodimers and their interacting partners in breast cancer development [2] . We have previously shown that the ErbB3 binding protein EBP1 inhibited the growth of ErbB2/ErbB3 expressing breast cancer cell lines in response to HRG in part by downregulating protein levels of ErbB2 [21] . We now show here that the EBP1-induced inhibition of ErbB2 protein was due to changes at the level of both ErbB2 transcription and protein stability.
The ability of EBP1 to regulate ErbB2 at multiple levels was somewhat surprising. However, EBP1 has previously been demonstrated by both the biological and structural analysis to be multifunctional [30] . The crystal structure of EBP1 [30] reveals that it has domains that may interact with DNA, RNA, and protein. Indeed, many independent groups have demonstrated that EBP1 binds DNA [31, 32] , RNA [33] [34] [35] [36] , and proteins [15, 37, 38] with varying biological consequences. What controls this differential activity of EBP1 is unknown. EBP1 is a phosphoprotein and it is possible that specific post translational modifications may result in activation of different functions. For example, we have shown that phosphorylation of EBP1 at Ser363 is essential for its ability to bind DNA through interactions with Sin3A [39] . Extensive data from Ye's group indicate that phosphorylation of EBP1 at Ser 360 affects its interaction with nuclear AKT [37] , caspase 3 [40] , and Bre1 [28] .
We first found that steady state mRNA levels of ErbB2 were decreased in EBP1-transfected cells. Possible changes in transcriptional rate were suggested by studies indicating that EBP1 decreased the activity of a luciferase reporter construct containing the ErbB2 proximal promoter in cells that overexpress ErbB2. However, the activity of this promoter construct was not decreased by ectopic expression of EBP1 in cells with normal levels of ErbB2 expression, although mRNA levels were decreased. It is possible that a different complement of transcriptional activators exist in cells that express low levels of ErbB2 that are differentially affected by EBP1. Currently, we do not know if EBP1 inhibits the ErbB2 promoter directly, or through interactions with other proteins. EBP1 is a member of the SF 00553 protein family of DNA binding proteins, and thus may be predicted to bind directly to the ErbB2 promoter alone or in a complex of nuclear proteins. We previously showed via ChIP and EMSA analysis that EBP1 can directly bind to promoters containing E2F1 [19] or Androgen Response Elements [20, 24] . In addition, it is possible that EBP1 may interact with other transcriptional activators or repressors to decrease ErbB2 transcription. The 500-bp region of the ErbB2 promoter contains an Ap2c site. Proteins such as Wwox have been shown to inhibit ErbB2 transcription by interfering with Ap2c recruitment [41] . Whether or not EBP1 interacts with Wwox and Ap2c remains to be determined.
The protein levels of ErbB2 in both the BT474 and T47D EBP1 transfectants cannot be wholly accounted for by changes in mRNA levels. Thus, some additional EBP1-regulated processes may govern final protein levels. We unexpectedly found that ErbB2 protein stability was changed in EBP1 transfectants. EBP1 has no consensus sites for ubiquitin ligase activity. In addition, EBP1 does not bind directly to human ErbB2 ectopically expressed in murine cells [15] or endogenous ErbB2 in BT474 cells (data not shown). However, it is possible that EBP1 enhances the expression, activity or recruitment of E3 ligases such as Chip [27] or LRIG [42] that are important in ErbB2 ubiquitination and degradation. Of interest, EBP1 itself is subjected to ubiquitin-mediated degradation. EBP1 protein has two forms: a p42 form which is a tumor suppressor and a p48 form that is a tumor promoter [43] . E3 ubiquitin ligase hBRE1 can promote EBP1 ubiquitination and degradation in prostate cancer cell lines [28] . However, only the p42 tumor suppressor form is affected in human prostate cancer cells. In our studies, inhibition of proteasome activity did not induce the appearance of the p42 band, nor increase expression of the p48 form.
We have previously found that knock out of EBP1 in MCF-7 cells results in tamoxifen resistance. We similarly found that inhibition of EBP1 expression renders T47D cells tamoxifen resistant. To further explore the mechanism of this inhibiton, we found that blocking ErbB2 activity with Herceptin reversed the EBP1-induced tamoxifen resistance. Thus, we postulate that EBP1 may regulate tamoxifen sensitivity in part by modulating levels of ErbB2. Similarly, the transcription factor PAX2 represses ErbB2 transcription by competing with SRC-3 for binding to Estrogen response elements within an intronic region of the ErbB2 gene. The repression of ErbB2 transcription by PAX 2 results in tamoxifen sensitivity [44] .
In summary, we have found that ectopic expression of EBP1 suppresses ErbB2 protein levels in ER? human breast cancer cell lines that express ErbB2 at both high and low levels. EBP1 affected both the transcription of ErbB2 mRNA and ErbB2 protein levels by altering ErbB2 stability and enhancing ubiquitination. Abrogation of EBP1 protein expression rendered T47D cells tamoxifen resistant and this resistance was mediated via the ErbB2 pathway. Thus, restoration of EBP1 or EBP1 signaling pathways may provide a new alternative in hormone refractory breast cancer.
